Document ID: chunk:federal_register_of_legislation:F2024L01524:schedule:1:p21
Version: federal_register_of_legislation:F2024L01524
Segment Type: schedule
Provision Reference: sch 1 (pt 21/38)
Character Range: 65275–70507

diagnosis of ADHD for the purposes of administering this restriction is:
                                                       (i) the presence of pre-existing childhood symptoms of ADHD (onset during the developmental period, typically early to mid-childhood); and
                                                       (ii) documentation in the patient's medical records that an in-depth clinical interview with, or, obtainment of evidence from, either a: (a) parent, (b) teacher, (c) sibling, (d) third party, has occurred and which supports point (i) above.
C16155  P16155  CN16155  Nirmatrelvir and ritonavir    SARS-CoV-2 infection                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 16155
                                                       Patient must have received a positive nucleic acid test result; OR
                                                       Patient must have received a positive rapid antigen test (RAT) result; AND
                                                       Patient must not require hospitalisation for COVID-19 infection at the time of prescribing; AND
                                                       The treatment must be initiated within 5 days of symptom onset; OR
                                                       The treatment must be initiated as soon as possible after a diagnosis is confirmed where asymptomatic.
                                                       Patient must be at least 70 years of age.
                                                       Access to this drug through this restriction is permitted irrespective of vaccination status.
                                                       Where nucleic acid testing is used to confirm diagnosis, the result, testing date, location and test provider must be recorded on the patient record.
                                                       Where a RAT is used to confirm diagnosis, available information about the test result, testing date, location and test provider (where relevant) must be recorded on the patient record.
                                                       This drug is not PBS-subsidised for pre-exposure or post-exposure prophylaxis for the prevention of SARS-CoV-2 infection.
C16156  P16156  CN16156  Nirmatrelvir and ritonavir    SARS-CoV-2 infection                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 16156
                                                       Patient must have received a positive nucleic acid test result; OR
                                                       Patient must have received a positive rapid antigen test (RAT) result; AND
                                                       Patient must have at least one sign or symptom attributable to COVID-19; AND
                                                       Patient must not require hospitalisation for COVID-19 infection at the time of prescribing; AND
                                                       The treatment must be initiated within 5 days of symptom onset.
                                                       Patient must be both: (i) at least 50 years of age, (ii) at high risk.
                                                       For the purpose of administering this restriction, high risk is defined as either a past COVID-19 infection episode resulting in hospitalisation, or the presence of at least two of the following conditions:
                                                       1. The patient is in residential aged care,
                                                       2. The patient has disability with multiple comorbidities and/or frailty,
                                                       3. Neurological conditions, including stroke and dementia and demyelinating conditions,
                                                       4. Respiratory compromise, including COPD, moderate or severe asthma (required inhaled steroids), and bronchiectasis, or caused by neurological or musculoskeletal disease,
                                                       5. Heart failure, coronary artery disease, cardiomyopathies,
                                                       6. Obesity (BMI greater than 30 kg/m 2),
                                                       7. Diabetes type I or II, requiring medication for glycaemic control,
                                                       8. Renal impairment (eGFR less than 60mL/min),
                                                       9.